BRPI0311179A2 - 3-aminopirazóis tricíclicos n-substituídos como inibidores de receptor de pdfg - Google Patents

3-aminopirazóis tricíclicos n-substituídos como inibidores de receptor de pdfg

Info

Publication number
BRPI0311179A2
BRPI0311179A2 BRPI0311179A BR0311179A BRPI0311179A2 BR PI0311179 A2 BRPI0311179 A2 BR PI0311179A2 BR PI0311179 A BRPI0311179 A BR PI0311179A BR 0311179 A BR0311179 A BR 0311179A BR PI0311179 A2 BRPI0311179 A2 BR PI0311179A2
Authority
BR
Brazil
Prior art keywords
aminopyrazoles
receptor inhibitors
unsubstituted tricyclic
pdfg
pdfg receptor
Prior art date
Application number
BRPI0311179A
Other languages
English (en)
Inventor
Bengt Anders Brunmark
Chin Yung Ho
Dana L Johnson
Donald W Ludovici
Eric D Strobel
Hwa Kwo Yen
Jan L Sechler
Jay M Mei
Robert A Galemmo Jr
Robert W Tuman
Stuart Emanuel
Umar Maharoof
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BRPI0311179A2 publication Critical patent/BRPI0311179A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/65031—Five-membered rings having the nitrogen atoms in the positions 1 and 2
    • C07F9/65038—Five-membered rings having the nitrogen atoms in the positions 1 and 2 condensed with carbocyclic rings or carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Materials For Medical Uses (AREA)
BRPI0311179A 2002-05-15 2003-05-13 3-aminopirazóis tricíclicos n-substituídos como inibidores de receptor de pdfg BRPI0311179A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38073502P 2002-05-15 2002-05-15
PCT/US2003/015193 WO2003097609A1 (en) 2002-05-15 2003-05-13 N-substituted tricyclic 3-aminopyrazoles as pdfg receptor inhibitors

Publications (1)

Publication Number Publication Date
BRPI0311179A2 true BRPI0311179A2 (pt) 2016-06-21

Family

ID=29550005

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0311179A BRPI0311179A2 (pt) 2002-05-15 2003-05-13 3-aminopirazóis tricíclicos n-substituídos como inibidores de receptor de pdfg

Country Status (29)

Country Link
US (2) US7196110B2 (pt)
EP (1) EP1506175B1 (pt)
JP (1) JP2006502097A (pt)
KR (1) KR20040106554A (pt)
CN (1) CN100396670C (pt)
AR (1) AR040079A1 (pt)
AT (1) ATE427301T1 (pt)
AU (1) AU2003234567A1 (pt)
BR (1) BRPI0311179A2 (pt)
CA (1) CA2486097A1 (pt)
CR (1) CR7574A (pt)
DE (1) DE60326950D1 (pt)
EA (1) EA008770B1 (pt)
ES (1) ES2323952T3 (pt)
HR (1) HRP20041188A2 (pt)
IL (1) IL165197A0 (pt)
MX (1) MXPA04011320A (pt)
MY (1) MY138268A (pt)
NO (1) NO20045451L (pt)
NZ (1) NZ548796A (pt)
PE (1) PE20040758A1 (pt)
PL (1) PL374062A1 (pt)
RS (1) RS98804A (pt)
SA (1) SA03240431A (pt)
TW (1) TW200407311A (pt)
UA (1) UA80820C2 (pt)
UY (1) UY27811A1 (pt)
WO (1) WO2003097609A1 (pt)
ZA (1) ZA200410108B (pt)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL374062A1 (en) * 2002-05-15 2005-09-19 Janssen Pharmaceutica N.V. N-substituted tricyclic 3-aminopyrazoles as pdfg receptor inhibitors
CN1914179A (zh) * 2003-11-13 2007-02-14 詹森药业有限公司 用于生物分子靶标识别的固定的n－取代的三环3－氨基吡唑类
CA2551495A1 (en) * 2004-01-07 2005-07-28 Ambit Biosciences Corporation Conjugated small molecules
WO2005123048A2 (en) * 2004-06-21 2005-12-29 Proteome Sciences Plc Screening methods using c-abl, fyn and syk in combination with tau protein
US7652029B2 (en) * 2004-07-09 2010-01-26 Medisyn Technologies, Inc. Therapeutic compound and treatments
WO2006044682A1 (en) * 2004-10-13 2006-04-27 Ptc Therapeutics, Inc. Compounds for nonsense suppression, and methods for their use
JP2006321724A (ja) * 2005-05-17 2006-11-30 Tokyo Univ Of Science 抗腫瘍剤
US20080031866A1 (en) * 2006-06-20 2008-02-07 Eichenbaum Gary M Method for modulating the pharmacokinetics and metabolism of a therapeutic agent
EP2037954A4 (en) * 2006-06-20 2011-09-14 Janssen Pharmaceutica Nv METHOD FOR MODULATING PHARMACOKINETICS AND METABOLISM OF THERAPEUTIC USE
JPWO2008093639A1 (ja) 2007-01-29 2010-05-20 武田薬品工業株式会社 ピラゾール化合物
WO2008094896A1 (en) * 2007-01-31 2008-08-07 Janssen Pharmaceutica, N.V. N-substituted tricyclic 3-aminopyrazoles as anti-mitotic tubulin polymerization inhibitors
AU2008227875B2 (en) 2007-03-19 2014-06-12 Insuline Medical Ltd. Drug delivery device
US9220837B2 (en) 2007-03-19 2015-12-29 Insuline Medical Ltd. Method and device for drug delivery
US8622991B2 (en) 2007-03-19 2014-01-07 Insuline Medical Ltd. Method and device for drug delivery
EP2231229A1 (en) 2007-12-18 2010-09-29 Insuline Medical Ltd. Drug delivery device with sensor for closed-loop operation
RU2532893C2 (ru) 2008-11-07 2014-11-10 Инсьюлин Медикал Лтд. Устройство и способ доставки лекарственных средств
WO2011059784A1 (en) * 2009-10-29 2011-05-19 Bristol-Myers Squibb Company Tricyclic heterocyclic compounds
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
WO2012121168A1 (ja) * 2011-03-04 2012-09-13 国立大学法人京都大学 キナーゼ阻害剤
TWI553010B (zh) * 2012-04-12 2016-10-11 財團法人生物技術開發中心 雜環吡唑化合物，其製備方法及用途
AR091424A1 (es) 2012-06-13 2015-02-04 Incyte Corp Compuestos triciclicos sustituidos como inhibidores de receptores del factor de crecimiento del fibroplasto (fgfr)
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
WO2014039831A1 (en) 2012-09-07 2014-03-13 Takeda Pharmaceutical Company Limited SUBSTITUTED-1,4-DIHYDROPYRAZOLO[4,3-b]INDOLES
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
PE20151593A1 (es) 2013-03-14 2015-11-05 Newlink Genetics Corp Compuestos triciclicos como inhibidores de la inmunosupresion mediada por el metabolismo del triptofano
TWI649318B (zh) 2013-04-19 2019-02-01 英塞特控股公司 作為ｆｇｆｒ抑制劑之雙環雜環
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
CN105884828A (zh) * 2015-02-16 2016-08-24 上海迪诺医药科技有限公司 多环化合物、其药物组合物及应用
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
MX2017010673A (es) 2015-02-20 2018-03-21 Incyte Corp Heterociclos biciclicos como inhibidores de receptores del factor de crecimiento fibroblastico (fgfr).
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
EP3507278B1 (en) 2016-09-02 2021-01-27 Bristol-Myers Squibb Company Substituted tricyclic heterocyclic compounds
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
US11059784B2 (en) 2017-08-09 2021-07-13 Bristol-Myers Squibb Company Oxime ether compounds
WO2019032632A1 (en) 2017-08-09 2019-02-14 Bristol-Myers Squibb Company ALKYLPHENYL COMPOUNDS
MA52494A (fr) 2018-05-04 2021-03-10 Incyte Corp Formes solides d'un inhibiteur de fgfr et leurs procédés de préparation
CA3099116A1 (en) 2018-05-04 2019-11-07 Incyte Corporation Salts of an fgfr inhibitor
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
PE20221085A1 (es) 2019-10-14 2022-07-05 Incyte Corp Heterociclos biciclicos como inhibidores de fgfr
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
JP2023505258A (ja) 2019-12-04 2023-02-08 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式複素環
US11407750B2 (en) 2019-12-04 2022-08-09 Incyte Corporation Derivatives of an FGFR inhibitor
AR126102A1 (es) 2021-06-09 2023-09-13 Incyte Corp Heterociclos tricíclicos como inhibidores de fgfr
WO2023081923A1 (en) 2021-11-08 2023-05-11 Frequency Therapeutics, Inc. Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
CN114890987B (zh) * 2022-04-13 2023-12-19 万华化学集团股份有限公司 一种硫酚-噻吩配体及其制备方法、烯烃聚合催化剂及其制备方法、应用
CN114686427B (zh) * 2022-05-23 2022-07-29 中国人民解放军总医院第一医学中心 一种脾脏调节型b淋巴细胞及其制备方法与应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3928378A (en) * 1974-01-30 1975-12-23 Hoechst Co American Fused bicyclic aminopyrazoles
US4220776A (en) * 1978-12-21 1980-09-02 E. I. Du Pont De Nemours And Company N-(Pyridothienopyrazol)amides
US4140785A (en) * 1978-05-08 1979-02-20 E. I. Du Pont De Nemours And Company N-(benzothienopyrazol)amide antirhinoviral agents
US4420476A (en) * 1982-05-24 1983-12-13 Averst McKenna & Harrison, Inc. Benzofuro[3,2-c]pyrazol-3-amine derivatives
ES2108120T3 (es) * 1991-05-10 1997-12-16 Rhone Poulenc Rorer Int Compuestos bis arilicos y heteroarilicos mono- y biciclicos que inhiben tirosina quinasa receptora de egf y/o pdgf.
ATE239506T1 (de) * 1992-03-05 2003-05-15 Univ Texas Verwendung von immunokonjugate zur diagnose und/oder therapie der vaskularisierten tumoren
US5474765A (en) * 1992-03-23 1995-12-12 Ut Sw Medical Ctr At Dallas Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells
JPH0622109A (ja) 1992-07-03 1994-01-28 Fujitsu Ltd ファクシミリ装置およびファクシミリ情報サービス方式
JPH06100561A (ja) 1992-07-13 1994-04-12 Otsuka Pharmaceut Factory Inc ナフチリジン及びピリドピラジン誘導体
JP2997828B2 (ja) 1992-07-30 2000-01-11 株式会社大塚製薬工場 キノリン及びナフチリジン誘導体
JP3148960B2 (ja) 1993-04-12 2001-03-26 コニカ株式会社 写真用シアンカプラー
DE69415341T2 (de) 1993-09-15 1999-07-15 Merck Sharp & Dohme Kondensierte tricyclische heteroaromatische derivate als liganden des dopamin-rezeptor-subtyps
US5364881A (en) * 1993-11-15 1994-11-15 The Medical College Of Wisconsin Research Foundation, Inc. S-alkyl-isothioureido-amino acids and use thereof
JP3245765B2 (ja) 1994-07-05 2002-01-15 コニカ株式会社 写真用シアンカプラー
US5476932A (en) 1994-08-26 1995-12-19 Hoffmann-La Roche Inc. Process for producing N4-acyl-5'-deoxy-5-fluorocytidine derivatives
US5476851A (en) * 1994-09-08 1995-12-19 Rhone-Poulenc Rorer Pharmaceuticals, Inc. Pyrazolo[3,4-g]quinoxaline compounds which inhibit PDGF receptor protein tyrosine kinase
US5563173A (en) * 1994-12-22 1996-10-08 Research Development Foundation Anti-proliferative effects of sodium butyrate
EP0822788B1 (en) 1995-04-19 2002-09-04 Schneider (Usa) Inc. Drug release coated stent
EP1021182A1 (en) 1997-10-06 2000-07-26 Basf Aktiengesellschaft Indeno[1,2-c] pyrazole derivatives for inhibiting tyrosine kinase activity
JP2001518501A (ja) * 1997-10-06 2001-10-16 ビーエーエスエフ アクチェンゲゼルシャフト インデノ［１，２−ｃ］−、ナフト［１，２−ｃ］−およびベンゾ［６，７］シクロへプタ［１，２−ｃ］ピラゾール誘導体
JP4194678B2 (ja) 1997-11-28 2008-12-10 キリンファーマ株式会社 キノリン誘導体およびそれを含む医薬組成物
US5932580A (en) * 1997-12-01 1999-08-03 Yissum Research And Development Company Of The Hebrew University Of Jerusalem PDGF receptor kinase inhibitory compounds their preparation and compositions
CN1297442A (zh) 1998-04-21 2001-05-30 杜邦药品公司 用作抗癌剂和抗增殖剂的5－氨基茚并[1,2－c]吡唑－4－酮类化合物
US6291505B1 (en) 1998-08-07 2001-09-18 Chiron Corporation Estrogen receptor modulators
PT1165544E (pt) * 1999-04-06 2003-12-31 Abbott Gmbh & Co Kg 1,4-di-hidroindeno¬1,2-c|pirazoles substituidos como inibidores de tirosina-quinase
US6887468B1 (en) * 1999-04-28 2005-05-03 Board Of Regents, The University Of Texas System Antibody kits for selectively inhibiting VEGF
US6824987B1 (en) 1999-05-11 2004-11-30 President And Fellows Of Harvard College Small molecule printing
BR0110302A (pt) * 2000-04-18 2003-01-14 Agouron Pharma Compostos de pirazol para inibição de proteìnas cinase, sal e pró-droga farmaceuticamente aceitável, metabólito farmaceuticamente ativo ou sal farmaceuticamente aceitável de metabólito, composição farmacêutica, método de tratamento de condição doentia em mamìferos mediada pela atividade de proteìna cinase, método de modulação ou inibição da atividade de um receptor de proteìna cinase
US6776796B2 (en) * 2000-05-12 2004-08-17 Cordis Corportation Antiinflammatory drug and delivery device
KR100904157B1 (ko) 2000-08-10 2009-06-23 파마시아 이탈리아 에스.피.에이. 키나제 억제제로서 활성인 비사이클로-피라졸, 이의제조방법 및 이를 포함하는 약제학적 조성물
PL374062A1 (en) * 2002-05-15 2005-09-19 Janssen Pharmaceutica N.V. N-substituted tricyclic 3-aminopyrazoles as pdfg receptor inhibitors

Also Published As

Publication number Publication date
US20070142305A1 (en) 2007-06-21
CN1668601A (zh) 2005-09-14
EP1506175B1 (en) 2009-04-01
EA200401378A1 (ru) 2005-06-30
ES2323952T3 (es) 2009-07-28
AU2003234567A1 (en) 2003-12-02
US7196110B2 (en) 2007-03-27
MY138268A (en) 2009-05-29
PE20040758A1 (es) 2005-01-01
TW200407311A (en) 2004-05-16
NO20045451L (no) 2005-02-09
ZA200410108B (en) 2006-05-31
JP2006502097A (ja) 2006-01-19
DE60326950D1 (de) 2009-05-14
IL165197A0 (en) 2005-12-18
UA80820C2 (en) 2007-11-12
AR040079A1 (es) 2005-03-16
UY27811A1 (es) 2003-10-31
PL374062A1 (en) 2005-09-19
RS98804A (en) 2006-10-27
CA2486097A1 (en) 2003-11-27
CR7574A (es) 2008-09-10
EA008770B1 (ru) 2007-08-31
CN100396670C (zh) 2008-06-25
HRP20041188A2 (en) 2007-03-31
SA03240431A (ar) 2005-12-03
NZ548796A (en) 2008-01-31
WO2003097609A1 (en) 2003-11-27
KR20040106554A (ko) 2004-12-17
ATE427301T1 (de) 2009-04-15
EP1506175A1 (en) 2005-02-16
US7795440B2 (en) 2010-09-14
US20040082639A1 (en) 2004-04-29
MXPA04011320A (es) 2005-08-16

Similar Documents

Publication Publication Date Title
BRPI0311179A2 (pt) 3-aminopirazóis tricíclicos n-substituídos como inibidores de receptor de pdfg
IS8578A (is) 3- karbamoýl - 2- pýridón afleiður
ATE540936T1 (de) Substituierte 2-alkyl-chinazolinonderivate als parp-hemmer
ATE394399T1 (de) Tetrahydropyridoindolderivate
DK1761541T3 (da) Pyrrazolo-pyrimidin-derivater
ATE540935T1 (de) Chinazolinderivate
IS7662A (is) Ný þríhringlaga spírópíperídín eða spírópýrrólídín
DE502005010218D1 (de) Spiralbohrer
DE502005009133D1 (de) Hydraulik-dehnspannfutter
ZA200610771B (en) Quinazolinedolone derivatives as PARP inhibitors
ATE417830T1 (de) Sulfonylbenzimidazolderivate
ATE437876T1 (de) Hexahydropyridoisochinoline als dpp-iv- inhibitoren
ATE512960T1 (de) Pyrimidinderivate
ATE413389T1 (de) Chinazolinderivate
DK1781618T3 (da) Sigma-receptorinhibitorer
ATE430142T1 (de) Phenylpiperazin-methanon-derivate
IS8195A (is) Ásetnar pýrrólafleiður
DE602004019555D1 (de) Heterocyclische 7-aminoalkylidenylchinolone und -naphthyridone
DE602005024486D1 (de) Anthrapyridonfarbstoffe
ATE404542T1 (de) 4-phenylpyrimidin-2-carbonitrilderivate
DE60317239D1 (de) Entlüftbarer verteiler
ATE365731T1 (de) 4-amino-5-cyanopyrimidinderivate
DE112005001372T5 (de) Plattierungsvorrichtung
DE602005002751D1 (de) Substituierte tricyclische benzimidazole
DE502004001207D1 (de) Schnellwechselbeschlag

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 9A, 10A, 11A, 12A E 13A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.